

Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) for colorectal cancer screening.

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON20182

Source

NTR

Brief title

DWIBS for colorectal cancer screening

Health condition

Colorectal cancer

Sponsors and support

Primary sponsor: University medical center, Utrecht, The Netherlands

Prof. dr. Siersema, MD, PhD

Department of Gastroenterology and Hepatology

University Medical Center Utrecht

P.O. Box 85500, 3508 GA Utrecht

Heidelberglaan 100, 3584 CX Utrecht

Tel.nr.: +31 88 7555555

Fax.nr.: +31 88 755 5533

E-mail: p.d.siersema@umcutrecht.nl

Source(s) of monetary or material Support: Initiator = sponsor

Intervention

Outcome measures

Primary outcome

Investigate whether DWIBS is effective for colorectal cancer screening.

Secondary outcome

Sensitivity of DWIBS for the detection of colorectal cancer and polyps > 6mm.

Study description

Background summary

The DWIBS-sequentie is a promising MRI-techniek for the early detection of colorectal cancer. We want to investigate whether DWIBS is effective for colorectal cancer screening.

Study objective

Investigate whether DWIBS is effective for colorectal cancer screening.

Study design

Inclusion of patients: 2 years.

Intervention

1. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS);
2. Colonoscopy.

Contacts

Public

University Medical Center Utrecht

P.O. Box 85500

A. Leufkens

Department of Gastroenterology and Hepatology

University Medical Center Utrecht
Heidelberglaan 100, 3584 CX Utrecht
Utrecht 3508 GA
The Netherlands
+31 887551057 / +31 88 7555555

Scientific

University Medical Center Utrecht
P.O. Box 85500
A. Leufkens
Department of Gastroenterology and Hepatology
University Medical Center Utrecht
Heidelberglaan 100, 3584 CX Utrecht
Utrecht 3508 GA
The Netherlands
+31 887551057 / +31 88 7555555

Eligibility criteria

Inclusion criteria

1. Age 50 years or older;
2. Patients who will undergo a colonoscopy because of the suspicion of having colorectal carcinoma, with at least one of the following symptoms: rectal blood loss, altered bowel habits, unexplained weight loss, abdominal pain, and/or anemia;
3. Written informed consent.

Exclusion criteria

1. General contra-indications for MRI (metal devices [pacemakers, endoprotheses, intra uterine devices, neurostimulators, insulin pump, intra-ocular parts of metal, ear implants, artificial metal cardiac valves], claustrophobia);
2. Weight >100kg;
3. A history of another malignancy;
4. Pregnant patients or patients lactating;
5. Patients in which therapy is already started.

Study design

Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Non controlled trial
Masking:	Single blinded (masking used)
Control:	N/A , unknown

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	09-01-2009
Enrollment:	390
Type:	Anticipated

Ethics review

Positive opinion	
Date:	19-12-2008
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL1527
NTR-old	NTR1599
Other	METC UMC Utrecht : 08-175
ISRCTN	ISRCTN wordt niet meer aangevraagd

Study results